TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17113685

Group type: EXPERIMENTAL
Intervention: B vitamins (2mg of folate, 25mg of B6, 400 microg of B12)
Number of subjects: 299

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 299
Study: 16154305

Group type: EXPERIMENTAL
Intervention: Psyllium (5.1g b.i.d.)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 11873030

Group type: COMPARATOR
Intervention: Norepinephrine
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Vasopressin
Number of subjects: 24
Study: 10468987

Group type: EXPERIMENTAL
Intervention: GH replacement therapy (0.036 U/kg/d)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 18
Study: 7595856

Group type: EXPERIMENTAL
Intervention: Exercise therapy at the anaerobic threshold (AT) level continued after discharge (group T)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (group C) with exercise therapy discontinued after discharge
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Both groups (T and C)
Number of subjects: 62
Study: 2112480

Group type: EXPERIMENTAL
Intervention: 100 g glucose and 120 g milk fat with 10 microCi U‐14C oleic acid given in the overnight fasting state
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 100 g glucose and 120 g milk fat with 10 microCi U‐14C oleic acid given 2 h after a carbohydrate-rich meal
Number of subjects: 16
Study: 521570

Group type: EXPERIMENTAL
Intervention: Methylphenidate (Ritalin)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31092670

Group type: EXPERIMENTAL
Intervention: Self-Help Plus (SH+)
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Enhanced treatment-as-usual
Number of subjects: 1200
Study: 28426857

Group type: EXPERIMENTAL
Intervention: Ready-made spectacles (n=232)
Number of subjects: 460

Group type: COMPARATOR
Intervention: Custom-made spectacles (n=228)
Number of subjects: 460
Study: 25565796

Group type: EXPERIMENTAL
Intervention: Umeclidinium 125 μg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Umeclidinium/vilanterol 125/25 μg
Number of subjects: 18
Study: 24288513

Group type: COMPARATOR
Intervention: 0 ppm nanocide in drinking water
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: 10 ppm nanocide in drinking water
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: 20 ppm nanocide in drinking water
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: 30 ppm nanocide in drinking water
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: 50 ppm nanocide in drinking water
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: 70 ppm nanocide in drinking water
Number of subjects: 270
Study: 21737469

Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring
Number of subjects: 892

Group type: COMPARATOR
Intervention: Self monitoring of blood glucose
Number of subjects: 892
Study: 19214042

Group type: EXPERIMENTAL
Intervention: Perceived carer criticism
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: High expressed emotion (EE)
Number of subjects: 67
Study: 17537292

Group type: EXPERIMENTAL
Intervention: Iron supplementation
Number of subjects: 2452

Group type: COMPARATOR
Intervention: No iron supplementation
Number of subjects: 2452
Study: 15848529

Group type: EXPERIMENTAL
Intervention: Reduction of MMF or AZA to 75% and then to 50% of the original dose at 4 months and 8 months after inclusion.
Number of subjects: 45
Study: 11205419

Group type: EXPERIMENTAL
Intervention: Moderate MDMA use
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Heavy MDMA use
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Ecstasy users (both moderate and heavy)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (no MDMA use)
Number of subjects: 62
Study: 9024731

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) with nitroglycerin (NTG) infusion
Number of subjects: 16

Group type: COMPARATOR
Intervention: Nitroglycerin (NTG) infusion alone
Number of subjects: 16
Study: 8335968

Group type: EXPERIMENTAL
Intervention: HIV-1-derived recombinant live vaccina-gp160
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Purified rgp160 (boost)
Number of subjects: 4

Group type: COMPARATOR
Intervention: CD8+ cell depletion
Number of subjects: 4

Group type: COMPARATOR
Intervention: HLA class I-mismatched target cells
Number of subjects: 4
Study: 3523041

Group type: EXPERIMENTAL
Intervention: Postoperatively administered plasma proteins
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control group (no plasma proteins)
Number of subjects: 94
Study: 2471718

Group type: EXPERIMENTAL
Intervention: SCH 434 (5 mg loratadine and 120 mg pseudoephedrine, administered twice daily)
Number of subjects: 435

Group type: EXPERIMENTAL
Intervention: Loratadine alone (component of SCH 434)
Number of subjects: 435

Group type: EXPERIMENTAL
Intervention: Pseudoephedrine alone (component of SCH 434)
Number of subjects: 435

Group type: EXPERIMENTAL
Intervention: SCH 434
Number of subjects: 435

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 435
Study: 31222628

Group type: EXPERIMENTAL
Intervention: Body fat percentage
Number of subjects: 18542

Group type: EXPERIMENTAL
Intervention: Height
Number of subjects: 18542
Study: 28970080

Group type: EXPERIMENTAL
Intervention: Vacc-4x
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study: 26995988

Group type: EXPERIMENTAL
Intervention: Early chemoradiotherapy (CRT) without induction chemotherapy (IC) by capecitabine
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Delayed CRT with 4 or 8 courses of IC by capecitabine
Number of subjects: 3

Group type: COMPARATOR
Intervention: Whole brain radiation therapy (historical control)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Overall survival rate
Number of subjects: 3
Study: 24132975

Group type: EXPERIMENTAL
Intervention: Methyl-d9-choline (22% of total choline intake, 480 or 930 mg/d)
Number of subjects: 47
Study: 20843868

Group type: EXPERIMENTAL
Intervention: Psychodynamic psychotherapy
Number of subjects: 94
Study: 19745163

Group type: EXPERIMENTAL
Intervention: Homocysteine stimulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inhibition of Sp1 and AP-1 activations by specific siRNA
Number of subjects: 0

Group type: COMPARATOR
Intervention: Preshearing of ECs for 1 to 4 hours at 20 dyn/cm2
Number of subjects: 0

Group type: COMPARATOR
Intervention: NO donor
Number of subjects: 0

Group type: COMPARATOR
Intervention: Inhibitor or siRNA for endothelial NO synthase
Number of subjects: 0
Study: 16283367

Group type: EXPERIMENTAL
Intervention: HRT+ (hormone replacement therapy)
Number of subjects: 45

Group type: COMPARATOR
Intervention: HRT- (no hormone replacement therapy)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Young subjects
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: HRT+
Number of subjects: 45

Group type: COMPARATOR
Intervention: HRT-
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: All groups (HRT+, HRT-, Young)
Number of subjects: 45
Study: 15332999

Group type: EXPERIMENTAL
Intervention: Exposure to radiation from the Chernobyl Power Station accident
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control group (matched by gender, birth year, and raion of residence)
Number of subjects: 78
Study: 10647724

Group type: EXPERIMENTAL
Intervention: LASIK with Chiron Hansatome microkeratome and Summit Apex Plus excimer laser
Number of subjects: 63
Study: 9077616

Group type: EXPERIMENTAL
Intervention: Chlorhexidine 0.2% solution
Number of subjects: 1024

Group type: COMPARATOR
Intervention: Placebo (sterile water)
Number of subjects: 1024
Study: 8435984

Group type: EXPERIMENTAL
Intervention: Insulin treatment
Number of subjects: 11

Group type: COMPARATOR
Intervention: Sulphonylureas
Number of subjects: 11
Study: 3711377

Group type: EXPERIMENTAL
Intervention: Tar oil applied twice daily with ultraviolet B phototherapy
Number of subjects: 22

Group type: COMPARATOR
Intervention: Oil vehicle (an emollient) applied twice daily with ultraviolet B phototherapy
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Tar oil in conjunction with ultraviolet B phototherapy
Number of subjects: 22
Study: 30572580

Group type: EXPERIMENTAL
Intervention: D-allulose at doses of 0.1 g/kg·BW to 1.0 g/kg·BW
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: D-allulose at 1.0 g/kg·BW
Number of subjects: 0
Study: 29083443

Group type: EXPERIMENTAL
Intervention: Health promotion and preventive care intervention (multi-topic personal reinforcement in small group sessions or preventive home visits)
Number of subjects: 2580

Group type: EXPERIMENTAL
Intervention: Health promotion and preventive care intervention
Number of subjects: 2580

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2580
Study: 25342738

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 26

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 26
Study: 22959058

Group type: EXPERIMENTAL
Intervention: High-saturated-fatty-acid (HSFA) meal
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: High-monounsaturated-fatty-acid (HMUFA) meal
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: High-polyunsaturated-fatty-acid (HPUFA) meal with n-3 PUFA
Number of subjects: 39

Group type: COMPARATOR
Intervention: High-polyunsaturated-fatty-acid (HPUFA) meal (placebo)
Number of subjects: 39
Study: 20567511

Group type: EXPERIMENTAL
Intervention: Richly fortified porridge
Number of subjects: 743

Group type: COMPARATOR
Intervention: Basal level porridge
Number of subjects: 743
Study: 18226561

Group type: EXPERIMENTAL
Intervention: Arm-cranking exercise
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Leg-cranking exercise
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care controls
Number of subjects: 0
Study: 17007343

Group type: EXPERIMENTAL
Intervention: Hydrofibre dressing (Aquacel)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Central pad dressing (Mepore)
Number of subjects: 61
Study: 14730292

Group type: EXPERIMENTAL
Intervention: Intraocular lens (IOL) implantation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Contact lens (CL) correction
Number of subjects: 30
Study: 10399047

Group type: EXPERIMENTAL
Intervention: Coping skills training
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Cognitive therapy according to Beck
Number of subjects: 120

Group type: COMPARATOR
Intervention: Supportive therapy
Number of subjects: 120
Study: 7554761

Group type: EXPERIMENTAL
Intervention: 99mTc‐DTPA (intra-arterial injection)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 99mTc‐DTPA (intravenous injection)
Number of subjects: 16

Group type: COMPARATOR
Intervention: 99mTc‐HSA (intra-arterial injection)
Number of subjects: 16
Study: 2188543

Group type: EXPERIMENTAL
Intervention: 125 mg of intravenous methylprednisolone
Number of subjects: 81

Group type: COMPARATOR
Intervention: Intravenous normal saline (control)
Number of subjects: 81
Study: 6110916

Group type: EXPERIMENTAL
Intervention: Imotest (disposable liquid tuberculin PPD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mantoux test
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Imotest
Number of subjects: 0
Study: 31743812

Group type: EXPERIMENTAL
Intervention: Fish oil (FO) lipid emulsion, reduced to 0.4 g/kg daily
Number of subjects: 19

Group type: COMPARATOR
Intervention: Olive/soybean (O/S) lipid emulsion, reduced to 0.4 g/kg daily
Number of subjects: 19
Study: 30339669

Group type: EXPERIMENTAL
Intervention: Three-week upper-extremity intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Demographic characteristics and movement features
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LASSO model
Number of subjects: 0
Study: 26679058

Group type: EXPERIMENTAL
Intervention: In-field gait retraining programme using mobile biofeedback, increasing step rate by 7.5% over preferred for 8 routine in-field runs.
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (not specified what intervention was provided).
Number of subjects: 30
Study: 24886392

Group type: EXPERIMENTAL
Intervention: Intervention includes provision of kits with necessary medicines and laboratory supplies for ANC, a storage system, a tracking system, and training sessions for health care providers.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intervention (first ANC visit)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intervention (second and higher ANC visits)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intervention
Number of subjects: 0
Study: 23206490

Group type: EXPERIMENTAL
Intervention: Intra-operative intra-articular injection of magnesium sulphate and ropivacaine
Number of subjects: 80

Group type: COMPARATOR
Intervention: Normal saline injection (control)
Number of subjects: 80
Study: 20159292

Group type: EXPERIMENTAL
Intervention: MRI (n=816)
Number of subjects: 1623

Group type: COMPARATOR
Intervention: No MRI (n=807)
Number of subjects: 1623
Study: 17630552

Group type: EXPERIMENTAL
Intervention: Genital HSV‐2 infection
Number of subjects: 441

Group type: EXPERIMENTAL
Intervention: Cervicovaginal HSV‐2 DNA
Number of subjects: 441

Group type: EXPERIMENTAL
Intervention: Cervicovaginal HIV‐1 RNA and HSV‐2 DNA correlation
Number of subjects: 441
Study: 15810770

Group type: EXPERIMENTAL
Intervention: Single reminder trial
Number of subjects: 0
Study: 11977510

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 29
Study: 9643054

Group type: EXPERIMENTAL
Intervention: Visual feedback
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Visual + auditory feedback
Number of subjects: 36

Group type: COMPARATOR
Intervention: Auditory feedback
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Distracting speech
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Mood
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Increased trait anxiety
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Expectation
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Increased anger-hostility, state-anxiety, and expectation
Number of subjects: 36
Study: 8135721

Group type: EXPERIMENTAL
Intervention: Cognitive-behavior therapy alone
Number of subjects: 21

Group type: COMPARATOR
Intervention: Desipramine alone
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Cognitive-behavior therapy combined with desipramine
Number of subjects: 21
Study: 2674084

Group type: EXPERIMENTAL
Intervention: Intravenous polyclonal 90‐Yttrium (90Y) labeled antiferritin, 10 mCi (1 patient), 20 mCi (4 patients), or 30 mCi (2 patients)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Intravenous polyclonal 90‐Yttrium (90Y) labeled antiferritin
Number of subjects: 6
Study: 46959

Group type: EXPERIMENTAL
Intervention: Intra-articular injection of yttrium-90 (irradiation)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Surgical synovectomy (control)
Number of subjects: 17
Study: 30717707

Group type: EXPERIMENTAL
Intervention: Capecitabine with high-dose radiotherapy (arms C + D)
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Capecitabine with standard-dose radiotherapy (arms A + B)
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Capecitabine with high-dose radiotherapy and nelfinavir (arms A + C)
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Capecitabine with standard-dose radiotherapy and nelfinavir (arms B + D)
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Three more cycles of GEMABX (arm E)
Number of subjects: 262

Group type: COMPARATOR
Intervention: All treatment arms
Number of subjects: 262
Study: 28494751

Group type: EXPERIMENTAL
Intervention: Droxidopa
Number of subjects: 460

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 460
Study: 25710876

Group type: EXPERIMENTAL
Intervention: Terbutaline (0.5 mg) administered by inhalation 15 min before EVH
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo administered by inhalation 15 min before EVH
Number of subjects: 85
Study: 23011012

Group type: EXPERIMENTAL
Intervention: PCV13
Number of subjects: 180

Group type: COMPARATOR
Intervention: PCV7
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: PCV13 and PCV7
Number of subjects: 180
Study: 21601418

Group type: EXPERIMENTAL
Intervention: Monocular occlusion pupillometer
Number of subjects: 49

Group type: COMPARATOR
Intervention: Free-viewing autorefractor pupillometer
Number of subjects: 49
Study: 19370171

Group type: EXPERIMENTAL
Intervention: Plitidepsin 5mg/m2 (Arm A)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Plitidepsin 7mg/m2 with L-carnitine (Arm B)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Both arms (Arm A and Arm B)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Coadministration of L-carnitine
Number of subjects: 39
Study: 16416227

Group type: EXPERIMENTAL
Intervention: High-caloric meal (3 kcal/min)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Low-caloric meal (1 kcal/min)
Number of subjects: 8
Study: 15633483

Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy (RT) after adequate local excision (LE)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adjuvant tamoxifen
Number of subjects: 0
Study: 11737438

Group type: EXPERIMENTAL
Intervention: 3% diclofenac gel in 2.5% hyaluronan gel
Number of subjects: 96

Group type: COMPARATOR
Intervention: Inactive gel vehicle (placebo)
Number of subjects: 96
Study: 9067953

Group type: EXPERIMENTAL
Intervention: Intravenous cyclosporine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cyclosporine (high doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cyclosporine in combination with corticosteroids
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 7645572

Group type: EXPERIMENTAL
Intervention: Scheduled bright light of 6,000‐12,000 lux on at least half of their 12‐hr night shifts for 3 months
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Ambient light of 1,200‐1,500 lux
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Bright light technology
Number of subjects: 13
Study: 2665389

Group type: EXPERIMENTAL
Intervention: Ampicillin/Gentamycin
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: Cefotiam (Halospor)
Number of subjects: 354

Group type: COMPARATOR
Intervention: Untreated group
Number of subjects: 354
Study: 342619

Group type: EXPERIMENTAL
Intervention: Influenza virus vaccine (A/New Jersey/76 [Hsw1N1]) from four different manufacturers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Split‐product vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Local reaction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All four vaccines
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Split‐virus vaccine
Number of subjects: 0
Study: 30880442

Group type: EXPERIMENTAL
Intervention: Nutritional supplement containing a mixture of carotenoids, vitamins and omega-3 fatty acids (1 tablet/day)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 31137872

Group type: EXPERIMENTAL
Intervention: Technical socks
Number of subjects: 109

Group type: COMPARATOR
Intervention: Non-technical socks
Number of subjects: 109
Study: 29262509

Group type: EXPERIMENTAL
Intervention: Weitan Waifu patch
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 25143719

Group type: EXPERIMENTAL
Intervention: Testosterone-enanthate (125 mg/week)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Finasteride (5 mg/day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Vehicle (placebo)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (for finasteride)
Number of subjects: 60
Study: 22421906

Group type: EXPERIMENTAL
Intervention: 280 mg red wine polyphenols
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: 560 mg red wine polyphenols
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Both doses of polyphenol treatment
Number of subjects: 61
Study: 20307804

Group type: EXPERIMENTAL
Intervention: Expanded tobacco‐use 'vital sign' intervention combined with fax referral to a quitline
Number of subjects: 1817

Group type: COMPARATOR
Intervention: Traditional tobacco‐use vital sign alone
Number of subjects: 1817
Study: 18353060

Group type: EXPERIMENTAL
Intervention: 200 IU/kg vitamin D
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: 400 IU/kg vitamin D
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: 800 IU/kg vitamin D
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 37
Study: 15647405

Group type: EXPERIMENTAL
Intervention: EHCSS1
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: EHCSS2
Number of subjects: 110

Group type: COMPARATOR
Intervention: CC2
Number of subjects: 110

Group type: COMPARATOR
Intervention: CC1
Number of subjects: 110

Group type: COMPARATOR
Intervention: No smoking
Number of subjects: 110
Study: 12639061

Group type: EXPERIMENTAL
Intervention: Quality of Life in Epilepsy (QOLIE)-89
Number of subjects: 0
Study: 10707140

Group type: EXPERIMENTAL
Intervention: Timolol 0.5%
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Betaxolol 0.5%
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 7797777

Group type: EXPERIMENTAL
Intervention: recombinant tissue‐type plasminogen activator (rt‐PA)
Number of subjects: 395

Group type: COMPARATOR
Intervention: primary coronary angioplasty
Number of subjects: 395
Study: 2121359

Group type: EXPERIMENTAL
Intervention: Selegiline (10 mg, once daily)
Number of subjects: 40

Group type: COMPARATOR
Intervention: L-acetylcarnitine (500 mg, twice daily)
Number of subjects: 40
Study: 219491

Group type: EXPERIMENTAL
Intervention: beta-blocker
Number of subjects: 10294

Group type: EXPERIMENTAL
Intervention: diuretic
Number of subjects: 10294

Group type: EXPERIMENTAL
Intervention: central antihypertensive agent
Number of subjects: 10294
Study: 30981150

Group type: EXPERIMENTAL
Intervention: Experimental pain induced by ultrasound‐guided injection of 1 mL hypertonic saline into the upper part of the right tibialis posterior muscle
Number of subjects: 12

Group type: COMPARATOR
Intervention: Isotonic saline as non‐pain‐inducing control
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Experimental pain
Number of subjects: 12
Study: 25854455

Group type: EXPERIMENTAL
Intervention: 0.9% normal saline (non-balanced group)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sterofundin®ISO (balanced group)
Number of subjects: 30
Study: 26118476

Group type: EXPERIMENTAL
Intervention: VivaGel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 23569144

Group type: EXPERIMENTAL
Intervention: 1 mg/kg GTW daily, orally for 52 weeks
Number of subjects: 39

Group type: COMPARATOR
Intervention: 4 g 5-ASA daily, orally for 52 weeks
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: GTW
Number of subjects: 39

Group type: COMPARATOR
Intervention: 5-ASA
Number of subjects: 39